Whether you’re selling a complete company, carving out a division or preparing for a public offering, A&M can provide the necessary divestiture support to maximize exit value and allow management to focus on maintaining business performance.
We provide a hands-on approach, working closely with management and its other advisers to help transition your business from a private company to a public company.
Companies, private equity and hedge funds, and investors deal with transactional information that is recorded at fair value, which often differs from cost. Understanding this difference and its impact on your business is crucial. A&M gets to the core value and what it means for you.
Managing Directors Vincent Mekles and Joe Shepley outline key steps organizations should take to proactively address the new Rule including how to assess employee and vendor risk and build defensible compliance controls.
For decades, the United States has shouldered a disproportionate share of global pharmaceutical costs, accounting for 70% of global biopharma profits and over 80% of new drug launches. While this has helped drive significant medical innovation and supported the majority of global drug launches, it has also resulted in higher out-of-pocket costs for American patients.
As the maritime world sails deeper into digital waters, cyber threats are no longer just an IT issue — they’re a boardroom priority. Discover the critical actions executives must take to safeguard resilience, reputation, and deal value in a high-stakes, high-risk seascape.
The KSA Banking Pulse, analyzes the performance of KSA's 10 largest listed banks for q1 2025, and highlights a strong start to the year marked by improved profitability, cost discipline, and accelerating corporate credit growth.